ethyl-2 thiacyclopentene-2 | 59121-27-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氢噻吩类
• 英文名称: ethyl-2 thiacyclopentene-2
• 英文别名: 2,3-Dihydro-5-ethylthiophen；2-Ethyl-4,5-dihydrothiophene；5-ethyl-2,3-dihydrothiophene
• CAS: 59121-27-6
• 化学式: C₆H₁₀S
• 分子量: 114.211
• InChiKey: VBOZZIMZLMYLBC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  6-Mercapto-hex-2-in 生成 ethyl-2 thiacyclopentene-2
  参考文献：
  名称：

  DUPUY C.; CROZET M.-P.; SURZUR J.-M., BULL. SOC. CHIM. FRANCE, 1980, PART 2, NO 7-8, 361-373

  摘要：

  DOI：

文献信息

• [EN] CEPHALOSPORIN DERIVATIVES USEFUL AS ß-LACTAMASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS DE LA CÉPHALOSPORINE UTILES COMME INHIBITEURS DE LA ?-LACTAMASE ET LEURS COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：DMITRIENKO GARY IGOR

  公开号：WO2011103686A1

  公开（公告）日：2011-09-01

  The present invention relates to cephalosporin derivatives having β- lactamase inhibitory activity. The compounds are useful in preventing or treating bacterial resistance to an antibiotic, e.g. a β-lactam antibiotic. Disclosed herein are compounds that are inhibitors of class B metallo-β-lactamases, as well as class A, C, and D serine β-lactamases. In some preferred embodiments, the compounds are 3'- thiobenzoate derivatives of a cephalosporin. Pharmaceutical compositions, methods, uses, kits and commercial packages comprising the compounds are also disclosed.

  本发明涉及具有β-内酰胺酶抑制活性的头孢菌素衍生物。这些化合物在预防或治疗细菌对抗生素，例如β-内酰胺类抗生素的抗药性方面是有用的。本发明揭示了一些抑制B类金属-β-内酰胺酶以及A类、C类和D类丝氨酸β-内酰胺酶的化合物。在一些首选实施例中，这些化合物是头孢菌素的3'-硫代苯甲酸酯衍生物。此外，还披露了包含这些化合物的制药组合物、方法、用途、试剂盒和商业包装。
• Heterocyclic self-immolative Linkers and Conjugates
  申请人：Feng Bainian

  公开号：US20090041791A1

  公开（公告）日：2009-02-12

  The present invention provides heterocyclic linker compounds useful for linking drug moieties to ligands. The compounds also include drug-ligand conjugates comprising a ligand capable of targeting a selected cell population, and a drug connected to the ligand by a heterocyclic linker moiety. The linker moiety comprises a peptide sequence that is a substrate for an intracellular enzyme, for example a cathepsin, that cleaves the peptide at an amide bond. The peptide further contains a self-immolating moiety which connects the drug and the protein peptide sequence. Upon cleavage of the peptide sequence by an intracellular enzyme the self-immolating moiety cleaves itself from the drug moiety such that the drug moiety is in an underivatized and active form.

  本发明提供了杂环连接剂化合物，用于将药物部分与配体连接。该化合物还包括药物-配体共轭物，包括一种能够针对选定细胞群体的配体，以及通过杂环连接基团与配体连接的药物。连接基团包括一种肽序列，该肽序列是细胞内酶的底物，例如蛋白酶，它在酰胺键处剪切肽。该肽进一步包含自行解离基团，连接药物和蛋白质肽序列。当细胞内酶剪切肽序列时，自行解离基团从药物部分中解离出来，使药物部分处于未衍生化和活性形式。
• COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH
  申请人：GRAY Nathanael S.

  公开号：US20110207736A1

  公开（公告）日：2011-08-25

  Provided are compounds and methods for treating or preventing kinase-mediated disorders therewith.

  提供了化合物和方法，用于治疗或预防由激酶介导的疾病。
• Imidazo[4,5-C]pyridine compounds and methods of antiviral treatment
  申请人：K.U.Leuven Research & Development

  公开号：EP2546254A1

  公开（公告）日：2013-01-16

  The present invention relates to pharmaceutical compositions for the treatment or prevention of viral infections comprising as an active principle at least one imidazo[4,5-c]pyridine prodrug having the general formula (A): wherein the substituents are described in the specification. The invention also relates to processes for the preparation and screening of compounds according to the invention having above mentioned general formula and their use in the treatment or prophylaxis of viral infections.

  本发明涉及用于治疗或预防病毒感染的药物组合物，其活性成分包括至少一种具有通式（A）的咪唑并[4,5-c]吡啶原药： 其中取代基见说明书。 本发明还涉及根据本发明制备和筛选具有上述通式的化合物的工艺及其在治疗或预防病毒感染中的用途。
• Imidazo[1,2-a]pyrazine compounds for treatment of viral infections such as hepatitis
  申请人：Biofocus DPI Limited

  公开号：EP2567960A2

  公开（公告）日：2013-03-13

  Novel imidazopyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a viral infection, in particular a HCV, HRV, Sb and/or CVB in a patient in need thereof.

  本发明公开了新型咪唑吡嗪化合物，其分子式如下： 这些化合物可制备成药物组合物，并可用于预防和治疗病毒感染，特别是有需要的患者的 HCV、HRV、Sb 和/或 CVB。